Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding these clinical trials, please contact 313-576-9790.

To view the current issue online, please click here.

### Bone Marrow Clinical Trials

#### BONE MARROW TRANSPLANT

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Phase</th>
<th>Therapeutic</th>
</tr>
</thead>
<tbody>
<tr>
<td>E2906</td>
<td>Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age≥ or equal to 60 Years)</td>
<td>III</td>
<td>Therapeutic</td>
</tr>
</tbody>
</table>

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9276. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org.

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Phase</th>
<th>Therapeutic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011-086</td>
<td>A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.</td>
<td>NA</td>
<td>Therapeutic</td>
</tr>
</tbody>
</table>

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9276. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org.

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Phase</th>
<th>Therapeutic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011-151</td>
<td>A Phase II Study Using High Dose Busulfan and Bortezomib as part of Allogeneic Transplant Conditioning Regimen for High Risk Multiple Myeloma Patients.</td>
<td>II</td>
<td>Therapeutic</td>
</tr>
</tbody>
</table>

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9276. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org.
### STUDY 2008-092
**Phase II**
**Therapeutic**
**Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients who have Failed to Respond to Steroid Treatment for Acute GVHD**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9276. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### STUDY 2009-150
**Phase II**
**Therapeutic**
**A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9276. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### STUDY BMTCTN0702
**Phase III**
**Therapeutic**
**A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant With Lenalidomide Maintenance for Patient with Multiple Myeloma.**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9276. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### STUDY 2009-162
**Phase III**
**Therapeutic**
**A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (Brentuximab Vedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma (HL) Following Autologous Stem Cell Transplant (ASCT).**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9276. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### IMMUNOTHERAPY
### STUDY 2011-025
**Phase I**
**Therapeutic**
**Treatment of Advanced Colorectal or Pancreatic Cancer with anti-CD3 x anti-Erbilux® Armed Activated T Cells (Phase Ib)**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9272. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### Breast Clinical Trials
### ADJUVANT
### STUDY B-47
**Phase III**
**Therapeutic**
**A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**STUDY 2011-026**
Phase II  
Therapeutic

**SCUSF 0806** Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (Neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin®)

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**STUDY MA32**
Phase III  
Therapeutic

A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**STUDY B-49**
Phase III  
Therapeutic

A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**ADJUVANT HORMONAL**

**STUDY S1007**
Phase III  
Therapeutic

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score RS) of 25 or Less

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**ADJUVANT RADIATION**

**STUDY RTOG1005**
Phase III  
Therapeutic

A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost versus Standard Whole Breast Irradiation plus Sequential Boost for Early-Stage Breast Cancer

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**STUDY RTOG0933**
Phase II  
Therapeutic

A Phase II Trial Hippocampal Avoidance during Whole Brain Radiotherapy for Brain Metastases

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**NEOADJUVANT**

**STUDY 2010-056**
Phase II  
Therapeutic

A Phase II Study of Anti-CD3 x Anti-HER2/neu (Her2Bi) Armed Activated T Cells (ATC) after Neoadjuvant Chemotherapy in Patients with HER2/neu (0-2+)- Negative Stage II-III Breast Cancers
<table>
<thead>
<tr>
<th>STUDY</th>
<th>Phase</th>
<th>Therapeutic</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>S0800</td>
<td>II</td>
<td>Therapeutic</td>
<td>A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (NAP-PACLITAXEL) (NSC-736631) with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer. For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a>.</td>
</tr>
<tr>
<td>E3108</td>
<td>II</td>
<td>Therapeutic</td>
<td>A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen. For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a>.</td>
</tr>
<tr>
<td>2010-008</td>
<td>I/II</td>
<td>Therapeutic</td>
<td>A Phase 1/2 Dose-Escalation Study of XL147 (SAR 245408) or XL765 (SAR 245409) in Combination with Letrozole in Subjects with Hormone Receptor-Positive and HER2-Negative Breast Cancer Refractory to a Nonsteroidal Aromatase Inhibitor. For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a>.</td>
</tr>
<tr>
<td>E3108</td>
<td>II</td>
<td>Therapeutic</td>
<td>A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen. For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a>.</td>
</tr>
<tr>
<td>2010-008</td>
<td>I/II</td>
<td>Therapeutic</td>
<td>A Phase 1/2 Dose-Escalation Study of XL147 (SAR 245408) or XL765 (SAR 245409) in Combination with Letrozole in Subjects with Hormone Receptor-Positive and HER2-Negative Breast Cancer Refractory to a Nonsteroidal Aromatase Inhibitor. For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a>.</td>
</tr>
<tr>
<td>ACRN6688</td>
<td>II</td>
<td>Therapeutic</td>
<td>Phase II Study of Fluroine-18 3'-Deoxy-3'-Flurothymidine(F-18-FLT) in Invasive Breast Cancer. For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a>.</td>
</tr>
</tbody>
</table>
# Gastrointestinal Clinical Trials

## ESOPHAGEAL

### STUDY 2011-003
- **Phase II**
- **Therapeutic**
- Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product (IMC-1121B) versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Stomach

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### STUDY RTOG0436
- **Phase III**
- **Therapeutic**
- A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

## PANCREATIC ADENOCARCINOMA

### STUDY 2011-015
- **Phase III**
- **Therapeutic**
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-Line Therapy for Metastatic Adenocarcinoma of the Pancreas

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### STUDY 2011-141
- **Phase I**
- **Therapeutic**
- Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated with Pancreatic Cancer

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### STUDY 2011-103
- **Phase II/III**
- **Therapeutic**
- A Phase II/III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### STUDY 2011-138
- **Phase II**
- **Therapeutic**
- A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination with Capecitabine for Subjects with Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP trial)

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Phase</th>
<th>Therapeutic</th>
<th>Description</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY RTOG0848</td>
<td>III</td>
<td>Therapeutic</td>
<td>A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY 2011-025</td>
<td>I</td>
<td>Therapeutic</td>
<td>Treatment of Advanced Colorectal or Pancreatic Cancer with anti-CD3 x anti-Erbitux® Armed Activated T Cells (Phase Ib)</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY S0809</td>
<td>II</td>
<td>Therapeutic</td>
<td>A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY 2009-135</td>
<td>I</td>
<td>Therapeutic</td>
<td>An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients with CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY C80702</td>
<td>III</td>
<td>Therapeutic</td>
<td>A Phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus CELECOXIB or PLACEBO for patients with resected stage III colon cancer</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY 2009-027</td>
<td>II</td>
<td>Therapeutic</td>
<td>A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) Versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Colorectal Cancer with Metastatic or Locally Advanced Disease</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY S0713</td>
<td>II</td>
<td>Therapeutic</td>
<td>A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-operative Therapy of Rectal Cancer</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY 2011-025</td>
<td></td>
<td></td>
<td>Treatment of Advanced Colorectal or Pancreatic Cancer with anti-CD3 x anti-Erbitux®</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>Study</td>
<td>Phase</td>
<td>Disease Area</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>--------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>STUDY 2011-068</td>
<td>Phase I/II</td>
<td>Therapeutic</td>
<td>Phase 1/2 Study of PX-866 and Cetuximab. For more information contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient contact the Karmanos Patient Concierge at 800-527-6266 or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>STUDY 2011-090</td>
<td>Phase III</td>
<td>Therapeutic</td>
<td>An Open-label, Randomized, Multi-Center, Phase III Study to Compare the Safety and Efficacy of TKI258 versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-Angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies. For more information contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient contact the Karmanos Patient Concierge at 800-527-6266 or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>STUDY 2011-042</td>
<td>Phase III</td>
<td>Therapeutic</td>
<td>A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer</td>
<td></td>
</tr>
<tr>
<td>Study #</td>
<td>Phase</td>
<td>Therapeutic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>---------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III Therapeutic</td>
<td>Vaccine in Patients Receiving Sunitinib as First-Line Therapy for Advanced/Metastatic Renal Cell Carcinoma</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROSTATE</td>
<td>STUDY 2012-001 Phase III Therapeutic</td>
<td>A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-Resistant Prostate Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>STUDY S0925 Phase II Therapeutic</td>
<td>A Randomized Phase II Study of Androgen Deprivation Combined with IMC-A12 Versus Androgen Deprivation Alone for Patients with New Hormone Sensitive Metastatic Prostate Cancer.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>STUDY 2007-128 Phase II Therapeutic</td>
<td>Phase II Trial of B-DIM (DIM: 3,3 diindolylmethane) on Intermediate Endpoint Biomarkers in Patients with Prostate Cancer who are Undergoing Prostatectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>STUDY S1014 Phase II Therapeutic</td>
<td>Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>STUDY 2010-130 Phase III Therapeutic</td>
<td>A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>STUDY 2011-031 Phase I/II Therapeutic</td>
<td>Phase I/II Trial to Establish the Safety and Preliminary Efficacy of the Combination of Docetaxel, Prednisone, and SOM 230 (Pasireotide) in Metastatic Castrate Resistant Prostate Cancer (CRPC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>STUDY 2012-044 Phase I/II Therapeutic</td>
<td>A Phase I/II Study of GDC-0068 or GDC-0980 with Abiraterone Acetate Versus Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer Previously</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Title</td>
<td>Details</td>
<td>Additional Contact Information</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Therapeutic</strong> Treated with Docetaxel-Based Chemotherapy</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2011-023</strong> Phase II Therapeutic</td>
<td>A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Trial Investigating Two Doses of EMD 525797 in Subjects with asymptomatic or Mildly Symptomatic Metastatic Castrate-Resistant Prostate Cancer (mCRPC)</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td>Therapeutic</td>
<td>Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY GOG-0263</td>
<td>Phase III</td>
<td>Randomized Phase III Clinical Trial of Adjuvant Radiation vs. Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVARY</td>
<td>STUDY NEW GOG-0273</td>
<td>Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY 2010-096</td>
<td>Phase III</td>
<td>A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/DOXIL/CAELYX) in Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY GOG-0261</td>
<td>Phase III</td>
<td>GOG-0261: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy - Naïve Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carinosarcoma (Mixed Mesodermal Tumors) of the Uterus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY GOG0213</td>
<td>Phase III</td>
<td>A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: (NSC #704865, IND #7921)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY 2963</td>
<td>Phase III</td>
<td>A Rand Ph III Trial of Maintenance Chemo Comparing 12 Mthly Cycles of Single Agent Paclitaxel or Xyotax(CT-2103) (IND#70177), vs No Treatment Until Documented Relapse in Women w/ Adv Ovarian or Primary Peritoneal Ca Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
UTERUS

STUDY NEW GOG-0238
Phase II
Therapeutic

A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

STUDY GOG-0261
Phase III
Therapeutic

A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy - Naïve Patients with Newly Diagnosed Stag I-IV Persistent or Recurrent Carinosarcoma (Mixed Mesodermal Tumors) of the Uterus

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

STUDY 2009-143
Phase I/II
Therapeutic

A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

GOG-0249
Phase III
Therapeutic

A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

Head & Neck Clinical Trials

STAGES I/II/III

STUDY 2011-176
Phase II
Therapeutic

An Open-label Phase 2 Study of ACE-041 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

STUDY RTOG0920
Phase III
Therapeutic

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

STAGES I - IV

STUDY RTOG1016
Phase III
Therapeutic

Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Stage</th>
<th>Phase</th>
<th>Trial Title</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2011-034</td>
<td>ANY STAGE</td>
<td>Phase II</td>
<td><strong>A Phase II of AT-101 in Combination with Docetaxel in Patients with Recurrent, Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</strong></td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY 2011-068</td>
<td>ANY STAGE</td>
<td>Phase I/II</td>
<td><strong>Phase 1/2 Study of PX-866 and Cetuximab</strong></td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
</tbody>
</table>

### Hematology Clinical Trials

#### MULTIPLE MYELOMA

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Stage</th>
<th>Phase</th>
<th>Trial Title</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY NEW 2011-098</td>
<td>ANN STAGE</td>
<td>Phase II</td>
<td><strong>C-MAP Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients with Relapsed and Refractory Disease</strong></td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY 2011-193</td>
<td>ANY STAGE</td>
<td>Phase III</td>
<td><strong>A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma</strong></td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY 2009-115</td>
<td>ANY STAGE</td>
<td>Phase I/II</td>
<td><strong>A Phase 1/2 Study of Array 520 in Patients with Relapsed or Refractory Multiple Myeloma</strong></td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>STUDY 2011-097</td>
<td>ANY STAGE</td>
<td>Phase I</td>
<td><strong>A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis</strong></td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td>Study Code</td>
<td>Study Title</td>
<td>Details</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY 2010-106</td>
<td>A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMYLOIDOSIS OR LIGHT CHAIN DEPOSITION DISEASE</td>
<td>A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan, and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY 2010-105</td>
<td>International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY 2010-108</td>
<td>An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL)- Amyloidosis Who Require Further Treatment</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEUKEMIA</td>
<td>Expanded Access Program of Ponatinib (AP24534) for Patients with Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY S0805</td>
<td>Phase II Study of Combination of Hyper-CVAD And Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia(Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT STUDY)</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
An Open-Label, Phase 1 Study Of Inotuzumab Ozogamicin in Subjects with Relapsed or Refractory CD22-Positive Acute Lymphocytic Leukemia

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL) (CALGB 10403)

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

A Phase 3, Multicenter, Randomized Study To Evaluate The Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Malignant Hematology Leukemia Subjects ≥ 60 Years old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High Risk Acute Promyelocytic Leukemia

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

Expanded Access Program of Ponatinib (AP24534) for Patients with Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org


For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Therapeutic</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase II Therapeutic</td>
<td>Using Early Interim FDG-PET Imaging</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>STUDY 2009-137</td>
<td>Treatment with SGN-35 in Patients with CD30-Positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>NON-HODGKIN'S AGRESSIVE (MANTLE CELL, LARGE B-CELL LYMPHOMA)</td>
<td>SWOG S1106: A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. RBendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients&lt; or= 65 Years of Age with Previously Untreated Mantle Cell Lymphoma</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>STUDY 2009-135</td>
<td>An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients with CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>STUDY 2011-028</td>
<td>An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin Administered in Combination with Rituximab Compared to Defined Investigator's Choice Therapy in Subjects with Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who are not Candidates for Intensive High-Dose Chemotherapy</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>STUDY 2009-137</td>
<td>Treatment with SGN-35 in Patients with CD30-Positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>STUDY 2009-100</td>
<td>An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
</tbody>
</table>
For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**T CELL**

**STUDY 2009-137**  
Phase II  
Therapeutic

**Treatment with SGN-35 in Patients with CD30-Positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**STUDY 2009-135**  
Phase I  
Therapeutic

**An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients with CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**MYELODYSPLASTIC SYNDROME (MDS)**

**STUDY E2905**  
Phase III  
Therapeutic

**Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

---

**Immunotherapy Clinical Trials**

**STUDY 2009-085**  
Phase II Therapeutic

**A Phase II Study of anti-CD3 x anti-HER2/neu Armed Activated T Cells for Patients with HER2/neu (0, 1+ or 2+) Metastatic Breast Cancers.**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9272. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**STUDY 2010-056**  
Phase II Therapeutic

**A Phase II Study of Anti-CD3 x Anti-HER2/neu (Her2Bi) Armed Activated T Cells (ATC) after Neoadjuvant Chemotherapy in Patients with HER2/neu (0-2+)-Negative Stage II-III Breast Cancers**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9272. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**STUDY 2011-025**  
Phase I Therapeutic

**Treatment of Advanced Colorectal or Pancreatic Cancer with anti-CD3 x anti- Erbitux® Armed Activated T Cells (Phase Ib)**

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9272. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

---

**RETURN TO TOP**
## Melanoma/Skin Clinical Trials

### ADJUVANT

**STUDY E1609**  
**Phase III**  
**Therapeutic**  

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### ADVANCED

**STUDY 2011-167**  
**Phase I**  
**Therapeutic**  

A Phase Ib, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Vemurafenib in Combination with GDC-0973 when Administered in BRAFV600E-Mutation Positive Patients, Previously Treated (but without Prior Exposure to BRAF or MEK Inhibitor Therapy) or Previously Untreated for Locally-Advanced/Unresectable or Metastatic Melanoma or Those Who Have Progressed after Treatment with Vemurafenib

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**STUDY 2010-144**  
**Phase II**  
**Therapeutic**  

A Randomized Phase II Study of Sequential Biotherapy with Aflibercept and High Dose IL-2 versus High Dose IL-2 alone in Patients with Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study (California Cancer Consortium Phi1-107/NCI 8628)

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

**STUDY 2011-085**  
**Phase II**  
**Therapeutic**  

An Open-Label, Single-Arm, Phase II, Multicenter Study to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients with Brain Metastases

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.  
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

### Neuro-Oncology Clinical Trials

There are currently no open clinical trials.

For more information on Karmanos Clincial Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

### Phase I Clinical Trials

---

**RETURN TO TOP**
The Karmanos Phase 1 Program is one of 14 National Cancer Institute funded Phase 1 Clinical Pharmacology Programs in North America. In hope of finding new and better ways to help cancer patients, Karmanos' Phase 1 Program has many clinical trials underway. Due to the specific requirements for patient eligibility, we are unable to post all of our open Phase 1 Clinical Trials in this newsletter. If you would like more information on our open Phase 1 Clinical Trials or to refer a patient, please contact Alima Patterson at 313-576-9428 or Tyrea Nash at 313-576-8765 or email phase1@karmanos.org.

All patients will need to go through an initial new patient screening consultation to determine if they are eligible for one of our Phase 1 studies and to ensure this is the best treatment option available for them.

### Sarcoma Clinical Trials

There are currently no open clinical trials.

For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

### Thoracic Clinical Trials

#### LUNG

**ADJUVANT**

<table>
<thead>
<tr>
<th>STUDY</th>
<th>Phase</th>
<th>Therapeutic</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E1505</td>
<td>III</td>
<td>Therapeutic</td>
<td>A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (&gt; 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)</td>
</tr>
</tbody>
</table>

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org.

**STAGE IV**

**ALK**

<table>
<thead>
<tr>
<th>STUDY</th>
<th>Phase</th>
<th>Therapeutic</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010-107</td>
<td>III</td>
<td>Therapeutic</td>
<td>Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated Patients with Non-Squamous Carcinoma of the Lung Harboring A Translocation or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus</td>
</tr>
</tbody>
</table>

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org.

**EGFR**

<table>
<thead>
<tr>
<th>STUDY</th>
<th>Phase</th>
<th>Therapeutic</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010-132</td>
<td>II</td>
<td>Therapeutic</td>
<td>A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination with OSI-906 or Placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene</td>
</tr>
</tbody>
</table>

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org.
OTHER GENETIC MARKER

STUDY NEW 2011-038
Phase III
Therapeutic
A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer Following Progression after, or Intolerance to, at Least One Prior Chemotherapy
For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

STUDY 2011-064
Phase II
Therapeutic
An Open Label Two-Stage Study of Orally Administered BKM120 in Patients with Metastatic Non-Small Cell Lung Cancer with Activated PI3K Pathway
For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

STUDY S0819
Phase III
Therapeutic
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

STAGE IV

STUDY S0709
Phase II
Therapeutic
S0709: A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected by Serum Proteomics
For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

RECURRENT ALK

STUDY 2012-002
Phase I/II
Therapeutic
A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK Rearranged Non-Small Cell Lung Cancer
For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

STUDY 2012-014
Phase II
Therapeutic
A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non-Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)
For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

EGFR

STUDY 2011-199
Phase I/II
Therapeutic
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Type</th>
<th>Stage</th>
<th>Therapeutic</th>
<th>Description</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2011-037</td>
<td>Phase II</td>
<td><strong>Therapeutic</strong></td>
<td>A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients with Stage IIIb or IV Non-Small Cell Lung Cancer</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>STUDY 2011-131</td>
<td>Phase II</td>
<td><strong>Therapeutic</strong></td>
<td>A Phase II, Multi-center, Open-label Study Evaluating the Efficacy and Safety of GRN1005 in Non-Small Cell Lung Cancer Patients with Brain Metastases</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td>STUDY 2009-024</td>
<td>Phase II</td>
<td><strong>Therapeutic</strong></td>
<td>Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
<td></td>
</tr>
<tr>
<td><strong>RECURRENT</strong></td>
<td>STUDY NEW 2012-003</td>
<td>Phase II</td>
<td><strong>Therapeutic</strong></td>
<td>A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab with and without GDC-0941 in Patients with Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td><strong>SCLC LIMITED</strong></td>
<td>STUDY CALGB 30610</td>
<td>Phase III</td>
<td><strong>Therapeutic</strong></td>
<td>Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Stage Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td><strong>MESOTHELIOMA</strong></td>
<td>STUDY S0905</td>
<td>Phase I/II</td>
<td><strong>Therapeutic</strong></td>
<td>A Phase I/Randomized Phase II Study of Cediranib (NSC #732208) versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
<tr>
<td><strong>OTHER</strong></td>
<td>STUDY 2008-048</td>
<td>Pilot</td>
<td><strong>Therapeutic</strong></td>
<td>A Pilot Study of Percutaneous Cryotherapy as Treatment for Stage I Lung Cancer or Solitary Metastatic Lung Cancer</td>
<td>For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email <a href="mailto:newpt@karmanos.org">newpt@karmanos.org</a></td>
</tr>
</tbody>
</table>
For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

STUDY 2011-140
Phase I
Therapeutic

Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients - Safety and Efficacy (ECLIPSE)

For more information on this trial contact the Karmanos Clinical Trials Office at 313-576-9790.
To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, or email newpt@karmanos.org

RETURN TO TOP